Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

P&G Reserves Right to Reinvent OTC Sleep Category

|Includes: The Procter & Gamble Company (PG), SOMX
P&G gained right-of-first refusal for the OTC rights to Silenor® in an Rx co-promotion deal with its originator, Somaxon Pharma, San Diego, CA (press release). Silenor® is a "new" Rx treatment for sleep disruption and insomnia that resurrects a well-known compound (doxepin) that first entered the US Rx market in 1969. Arguably there has been no new active ingredient introduced into the OTC sleep aid category in 30+ years.

Read More



Disclosure: No positions